Company: BLTE
Filing Date: 2025-10-22
Form Type: F-3ASR
Source: 0001104659-25-101403
Chunk: 19

Company: BELITE BIO, INC
Filing Date: 2025-10-22
Form: F-3ASR
Chunk 19
---
 of April 28, 2022, among us, the Depositary and all owners and holders from time to time of ADSs issued thereunder (the “Deposit Agreement”).

Subject to the terms of the Deposit Agreement and in compliance with the relevant requirements set out in the accompanying prospectus, you may turn in your ADSs to the Depositary for cancellation and withdrawal of the ordinary shares underlying your ADSs.

The Depositary will charge you fees for such cancellations pursuant to the Deposit Agreement.

You should carefully read the “Description of American Depositary Shares” section of this prospectus and the Deposit Agreement to better understand the terms of the ADSs.

Ordinary shares (including ordinary shares represented by ADSs) to be outstanding after this resale offering

34,890,991 ordinary shares (including ordinary shares represented by ADSs) or 36,844,115 ordinary shares (including ordinary shares represented by ADSs) if the Warrants are exercised in full.

Use of proceeds

We will not receive any proceeds from the sale of the ADSs by the Selling Shareholders under this prospectus, but will incur expenses in connection with the registration of these offered securities. However, we could receive up to approximately US$150 million in gross proceeds if the Warrants are exercised in full for cash. We cannot predict when or if the Warrants will be exercised. It is possible that the Warrants may expire and may never be exercised. We intend to use the net proceeds from the exercise of the Warrants for commercialization preparation, working capital and general corporate purposes.

See “Use of Proceeds” for more information.

Listing

The ADSs are listed on the Nasdaq Capital Market under the symbol “BLTE”. The Warrants will not be listed or quoted on any securities exchange.

Risk factors

Before deciding to invest in the ADSs, you should carefully consider the risks related to our business, the offering and our securities. See “Risk Factors” beginning on page 13 of this prospectus, and under similar headings in other documents incorporated by reference into this prospectus.

Deutsche Bank Trust Company Americas

<div align='center'>11</div>

TABLE OF CONTENTS

Depositary

The number of ordinary shares (including ordinary shares represented by ADSs) to be outstanding immediately after this resale offering as shown above is based on 34,890,991 ordinary shares (including ordinary shares represented by ADSs) outstanding as of September 30, 2025 and excludes the following as of that date:

•

5,